How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics, Inc. (NASDAQ:EDGE) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16.

What other stocks do shareholders of Edge Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX) , Amicus Therapeutics (FOLD) , McEwen Mining (MUX) , Cerecor (CERC) , Synergy Pharmaceuticals (SGYP) , Arena Pharmaceuticals (ARNA) , BioLineRx (BLRX) , Corbus Pharmaceuticals (CRBP) , CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE) .

NASDAQ:EDGE

Edge Therapeutics (EDGE) Stock Price, News & Analysis

→ Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad)

Free EDGE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.69
▼
$3.02
50-Day Range: $0.50
▼
$6.71
52-Week Range: $0.28
▼
$17.38

Volume: 1.13 million shs
Average Volume: 373,201 shs
Market Capitalization: $91.38 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Social Media

Get Edge Therapeutics alerts:

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.

Find out more here >>>

About Edge Therapeutics Stock (NASDAQ:EDGE)

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.

Ad Behind the Markets

Tiny Biotech Stock Wins $75 Billion Patent

Find out more here >>>

EDGE Stock News Headlines

April 19, 2024 | finance.yahoo.com

Peptide Therapeutics Market Projected to Reach $57.97 billion by 2030 - Exclusive Report by 360iResearch

April 18, 2024 | markets.businessinsider.com

Maintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy Results

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 18, 2024 | finance.yahoo.com

Panasonic and Shinobi Therapeutics Partner to Develop Efficient and Cost-Effective iPS Cell Therapy Manufacturing Technology

April 15, 2024 | finance.yahoo.com

Myeloid Therapeutics to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 15, 2024 | finance.yahoo.com

Gastrointestinal Therapeutics and Diagnostics: Propelling Global Markets with Cutting-Edge Technologies by BCC Research LLC

April 14, 2024 | msn.com

How cutting-edge therapies—like Ozempic—are changing the drug-pricing landscape

April 11, 2024 | msn.com

Prelude Therapeutics Unveils Promising Cancer Treatment Advances at AACR Meeting

April 19, 2024 | Behind the Markets (Ad)

Tiny Biotech Stock Wins $75 Billion Patent

April 4, 2024 | seekingalpha.com

Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management

April 4, 2024 | finance.yahoo.com

Myeloid Therapeutics to Showcase In Vivo CAR Data and its Diverse mRNA Platform at AACR

April 3, 2024 | benzinga.com

US Stocks Edge Lower; Private Employment Tops Views

April 3, 2024 | msn.com

Neighbors on edge after dog owner dead blocks away from Washington Avenue: 'Honestly kind of scared'

April 2, 2024 | finance.yahoo.com

Accelerating New Molecule Discovery: Rakovina Therapeutics AI Integration

April 2, 2024 | sg.finance.yahoo.com

UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels

April 1, 2024 | marketwatch.com

Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order

April 1, 2024 | finance.yahoo.com

GPCR Therapeutics Announces Publication in PNAS Using Cutting Edge Spectroscopy to Detect GPCR Heteromers on Live Cancer Cells

March 30, 2024 | seekingalpha.com

Crispr Therapeutics: Upcoming Catalysts May Validate The Bull Thesis And Force A Change In Plans

March 28, 2024 | uk.finance.yahoo.com

Global Metastatic Melanoma Therapeutics Market Anticipates Robust Growth with New Therapeutic Developments

March 27, 2024 | finance.yahoo.com

Is Indaptus Therapeutics (NASDAQ:INDP) In A Good Position To Invest In Growth?

March 27, 2024 | finance.yahoo.com

Companies Like Context Therapeutics (NASDAQ:CNTX) Could Be Quite Risky

March 22, 2024 | au.finance.yahoo.com

Q4 2023 Mink Therapeutics Inc Earnings Call

March 21, 2024 | finance.yahoo.com

Mirador Therapeutics Launches to Accelerate the Next Generation of Precision Medicines for Immune-mediated Diseases

March 20, 2024 | finanznachrichten.de

Phaxiam Therapeutics S.A.: PHAXIAM Announces 2023 Full-Year Results and Provides Business Update

March 19, 2024 | finance.yahoo.com

Tempo Therapeutics Secures Series A Financing to Advance Cutting-Edge Tissue Scaffold Products into Clinical Trials

March 19, 2024 | seekingalpha.com

Contineum Therapeutics Seeks $150 Million IPO For MS Treatments

March 19, 2024 | finanznachrichten.de

Telum Therapeutics appoints Dr. Subhendu Basu as CEO

See More Headlines

Receive EDGE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/01/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:EDGE
CUSIP: N/A
CIK: 1472091
Web: www.edgetherapeutics.com
Phone: (800) 208-3343
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,860,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -81.29%
Return on Assets: -56.92%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.59
Quick Ratio: 5.59

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.95 per share
Price / Book: 3.05

Miscellaneous

Outstanding Shares: 31,510,000
Free Float: N/A
Market Cap: $91.38 million
Optionable: Not Optionable
Beta: 3.65

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Frank K. Bedu-Addo
President, Chief Executive Officer & Director
Michael P. King
Chief Financial Officer
Lauren Wood
Chief Medical Officer
Gregory L. Conn
Chief Scientific Officer
Janetta Trochimiuk
Controller

Key Competitors

View All Competitors

EDGE Stock Analysis - Frequently Asked Questions

How were Edge Therapeutics' earnings last quarter?: Edge Therapeutics, Inc. (NASDAQ:EDGE) released its quarterly earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.27) by $0.16.
What other stocks do shareholders of Edge Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE).

This page (NASDAQ:EDGE) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Edge Therapeutics (EDGE) Stock Price, News & Analysis

About Edge Therapeutics Stock (NASDAQ:EDGE)

EDGE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

EDGE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info